Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Earle E Bain

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
The Journal of Clinical Psychiatry|September 19, 2017
Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in SmokersGeorge M Haig, Deli Wang, Jun Zhao, et al.
The American Journal of Psychiatry|March 5, 2016
A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in SchizophreniaGeorge M Haig, Earle E Bain, Weining Z Robieson, et al.
International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology|March 19, 2011
Sex differences in the neural correlates of autonomic arousal: a pilot PET studyAllison C Nugent, Earle E Bain, Julian F Thayer, et al.
Journal of Clinical Pharmacology|December 5, 2015
Mitigating the Effects of Nonadherence in Clinical TrialsThomas M Shiovitz, Earle E Bain, David J McCann, et al.
JMIR Mhealth and Uhealth|February 23, 2017
Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With SchizophreniaEarle E Bain, Laura Shafner, David P Walling, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 4, 2012
A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHDEarle E Bain, Weining Robieson, Yili Pritchett, et al.
Journal of Psychopharmacology (Oxford, England)|August 9, 2013
Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depressionAllison C Nugent, Paul J Carlson, Earle E Bain, et al.
The Journal of Clinical Psychiatry|July 17, 2012
A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorderEarle E Bain, George Apostol, R Bart Sangal, et al.
Biological Psychiatry|July 27, 2005
Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopyGregor Hasler, Alexander Neumeister, Jan Willem van der Veen, et al.
The American Journal of Psychiatry|November 3, 2005
Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorderKristine Erickson, Wayne C Drevets, Luke Clark, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
The Journal of Clinical Psychiatry|September 19, 2017
Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in SmokersGeorge M Haig, Deli Wang, Jun Zhao, et al.
The American Journal of Psychiatry|March 5, 2016
A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in SchizophreniaGeorge M Haig, Earle E Bain, Weining Z Robieson, et al.
International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology|March 19, 2011
Sex differences in the neural correlates of autonomic arousal: a pilot PET studyAllison C Nugent, Earle E Bain, Julian F Thayer, et al.
Journal of Clinical Pharmacology|December 5, 2015
Mitigating the Effects of Nonadherence in Clinical TrialsThomas M Shiovitz, Earle E Bain, David J McCann, et al.
JMIR Mhealth and Uhealth|February 23, 2017
Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With SchizophreniaEarle E Bain, Laura Shafner, David P Walling, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 4, 2012
A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHDEarle E Bain, Weining Robieson, Yili Pritchett, et al.
Journal of Psychopharmacology (Oxford, England)|August 9, 2013
Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depressionAllison C Nugent, Paul J Carlson, Earle E Bain, et al.
The Journal of Clinical Psychiatry|July 17, 2012
A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorderEarle E Bain, George Apostol, R Bart Sangal, et al.
Biological Psychiatry|July 27, 2005
Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopyGregor Hasler, Alexander Neumeister, Jan Willem van der Veen, et al.
The American Journal of Psychiatry|November 3, 2005
Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorderKristine Erickson, Wayne C Drevets, Luke Clark, et al.
Pageof 2